Sunesis Adds $15.5M

Sunesis Pharmaceuticals (NASDAQ: SNSS), the South San Francisco-based drug developer, said today it has raised $15.5 million in a new securities offering. The deal consists of shares of common stock and warrants to buy stock, Sunesis said. The cash will be used for the company’s pivotal clinical trial of vosaroxin, in combination with chemotherapy, for patients with relapsed forms of acute myeloid leukemia.

Trending on Xconomy